Fibrinogen in neurological diseases: mechanisms, imaging and therapeutics

[1]  Madelaine Daianu,et al.  Pericyte degeneration causes white matter dysfunction in the mouse central nervous system , 2018, Nature Medicine.

[2]  S. Love,et al.  Differing associations between Aβ accumulation, hypoperfusion, blood–brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  P. McGuire,et al.  The blood-brain barrier in psychosis. , 2018, The lancet. Psychiatry.

[4]  K. Nave,et al.  A bloody brake on myelin repair , 2017, Nature.

[5]  Mark Ellisman,et al.  Fibrinogen Activates BMP Signaling in Oligodendrocyte Progenitor Cells and Inhibits Remyelination after Vascular Damage , 2017, Neuron.

[6]  S. Strickland,et al.  Fibrinogen in the Nervous System: Glia Beware , 2017, Neuron.

[7]  B. Zlokovic,et al.  Alzheimer’s disease: A matter of blood–brain barrier dysfunction? , 2017, The Journal of experimental medicine.

[8]  C. Iadecola.  The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease , 2017, Neuron.

[9]  G. DeLuca,et al.  Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[10]  R. Perera,et al.  Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex , 2017, Annals of neurology.

[11]  M. Lynch,et al.  FTY720 Attenuates Infection-Induced Enhancement of Aβ Accumulation in APP/PS1 Mice by Modulating Astrocytic Activation , 2017, Journal of Neuroimmune Pharmacology.

[12]  D. Lodygin,et al.  Laquinimod enhances central nervous system barrier functions , 2017, Neurobiology of Disease.

[13]  K. Akassoglou,et al.  Alzheimer disease makes new blood contacts. , 2017, Blood.

[14]  S. Strickland,et al.  Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer disease mice. , 2017, Blood.

[15]  M. Jorge Cardoso,et al.  White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort , 2017, NeuroImage: Clinical.

[16]  B. Zlokovic,et al.  Regional early and progressive loss of brain pericytes but not vascular smooth muscle cells in adult mice with disrupted platelet-derived growth factor receptor-β signaling , 2017, PloS one.

[17]  H. Wiendl,et al.  Prothrombin and factor X are elevated in multiple sclerosis patients , 2016, Annals of neurology.

[18]  Dongmei Wang,et al.  Elevated fibrinogen levels in neuromyelitis optica is associated with severity of disease , 2016, Neurological Sciences.

[19]  S. Strickland,et al.  The Alzheimer's disease peptide β‐amyloid promotes thrombin generation through activation of coagulation factor XII: reply , 2016, Journal of thrombosis and haemostasis : JTH.

[20]  David A. Bennett,et al.  Relation of Cerebral Vessel Disease to Alzheimer’s Disease Dementia and Cognitive Function in Older Persons: A Cross-sectional Study , 2016, The Lancet Neurology.

[21]  C. Ruppert,et al.  Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells , 2016, Nature Communications.

[22]  S. Strickland,et al.  A role for thrombin in the brain and circulation in Alzheimer's disease , 2016 .

[23]  S. Strickland,et al.  A possible new role for Aβ in vascular and inflammatory dysfunction in Alzheimer's disease. , 2016, Thrombosis research.

[24]  Vicki Rosen,et al.  BMP signalling in skeletal development, disease and repair , 2016, Nature Reviews Endocrinology.

[25]  D. Lawrence,et al.  A CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo. , 2016, Blood.

[26]  T. Renné,et al.  The Alzheimer's disease peptide β‐amyloid promotes thrombin generation through activation of coagulation factor XII , 2016, Journal of thrombosis and haemostasis : JTH.

[27]  Douglas H. Smith,et al.  Blood-Brain Barrier Disruption Is an Early Event That May Persist for Many Years After Traumatic Brain Injury in Humans , 2015, Journal of Neuropathology and Experimental Neurology.

[28]  Zhen Zhao,et al.  Establishment and Dysfunction of the Blood-Brain Barrier , 2015, Cell.

[29]  M. Brug,et al.  Lack of Widespread BBB Disruption in Alzheimer’s Disease Models: Focus on Therapeutic Antibodies , 2015, Neuron.

[30]  D. Izquierdo-Garcia,et al.  Multisite Thrombus Imaging and Fibrin Content Estimation With a Single Whole-Body PET Scan in Rats , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[31]  W. Funkhouser,et al.  APOE Stabilization by Exercise Prevents Aging Neurovascular Dysfunction and Complement Induction , 2015, PLoS biology.

[32]  Victoria A. Rafalski,et al.  Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface , 2015, Front. Cell. Neurosci..

[33]  Sara G. Murray,et al.  Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation , 2015, Nature Communications.

[34]  Susan T Francis,et al.  Cerebrovascular and blood–brain barrier impairments in Huntington's disease: Potential implications for its pathophysiology , 2015, Annals of neurology.

[35]  Jiwon Kim,et al.  Direct Imaging of Cerebral Thromboemboli Using Computed Tomography and Fibrin-targeted Gold Nanoparticles , 2015, Theranostics.

[36]  M. Ota,et al.  Increased cerebrospinal fluid fibrinogen in major depressive disorder , 2015, Scientific Reports.

[37]  Britta Engelhardt,et al.  Brain barriers: Crosstalk between complex tight junctions and adherens junctions , 2015, The Journal of cell biology.

[38]  B. Frey,et al.  Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder? , 2015, Neural plasticity.

[39]  T. Korff,et al.  Dimethyl fumarate attenuates cerebral edema formation by protecting the blood–brain barrier integrity , 2015, Experimental Neurology.

[40]  Jesse D. Sengillo,et al.  GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration , 2015, Nature Neuroscience.

[41]  T. Renné,et al.  Activation of the factor XII-driven contact system in Alzheimer’s disease patient and mouse model plasma , 2015, Proceedings of the National Academy of Sciences.

[42]  T. Kanda,et al.  Fingolimod Prevents Blood-Brain Barrier Disruption Induced by the Sera from Patients with Multiple Sclerosis , 2015, PloS one.

[43]  J. Woulfe,et al.  Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  Lennart Thurfjell,et al.  Blood protein predictors of brain amyloid for enrichment in clinical trials? , 2015, Alzheimer's & dementia.

[45]  Sidney Strickland,et al.  Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration , 2015, Neurobiology of Aging.

[46]  C. Jack,et al.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly , 2015, Brain : a journal of neurology.

[47]  I. Ferrer,et al.  Fibrinogen-Derived γ377-395 Peptide Improves Cognitive Performance and Reduces Amyloid-β Deposition, without Altering Inflammation, in AβPP/PS1 Mice. , 2015, Journal of Alzheimer's disease : JAD.

[48]  Thomas Arzberger,et al.  Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies , 2015, Journal of Neural Transmission.

[49]  R. Aisina,et al.  Structure and function of plasminogen/plasmin system , 2014, Russian Journal of Bioorganic Chemistry.

[50]  D. Reich,et al.  The formation of inflammatory demyelinated lesions in cerebral white matter , 2014, Annals of neurology.

[51]  V. Gallo,et al.  Glial Development: The Crossroads of Regeneration and Repair in the CNS , 2014, Neuron.

[52]  Richard Nicholas,et al.  Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial , 2014, The Lancet.

[53]  S. Strickland,et al.  A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice , 2014, The Journal of experimental medicine.

[54]  A. Nimmerjahn,et al.  Stepwise Recruitment of Transcellular and Paracellular Pathways Underlies Blood-Brain Barrier Breakdown in Stroke , 2014, Neuron.

[55]  Jesse D. Sengillo,et al.  Blood–spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice , 2014, Proceedings of the National Academy of Sciences.

[56]  P. Carmeliet,et al.  Tissue plasminogen activator arrests Alzheimer's disease pathogenesis , 2014, Neurobiology of Aging.

[57]  Liping Tang,et al.  Optical imaging of fibrin deposition to elucidate participation of mast cells in foreign body responses. , 2014, Biomaterials.

[58]  R. Tsien,et al.  Early detection of thrombin activity in neuroinflammatory disease , 2014, Annals of neurology.

[59]  P. Taylor,et al.  Integrin CD11b positively regulates TLR4-induced signalling pathways in dendritic cells but not in macrophages , 2014, Nature Communications.

[60]  Hilkka Soininen,et al.  Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression. , 2014, Journal of Alzheimer's disease : JAD.

[61]  C. Iadecola,et al.  The Pathobiology of Vascular Dementia , 2013, Neuron.

[62]  C. Creighton,et al.  Cleavage of Fibrinogen by Proteinases Elicits Allergic Responses Through Toll-Like Receptor 4 , 2013, Science.

[63]  Protective effects of Batroxobin on spinal cord injury in rats , 2013, Neuroscience Bulletin.

[64]  D. Reich,et al.  Initial investigation of the blood-brain barrier in MS lesions at 7 tesla , 2013, Multiple sclerosis.

[65]  S. Strickland,et al.  The APOE ε4/ε4 Genotype Potentiates Vascular Fibrin(Ogen) Deposition in Amyloid-Laden Vessels in the Brains of Alzheimer's Disease Patients , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[66]  Mahlon D. Johnson,et al.  Deficiency in Mural Vascular Cells Coincides with Blood–Brain Barrier Disruption in Alzheimer's Disease , 2013, Brain pathology.

[67]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[68]  P. Grammas,et al.  Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia , 2013, Front. Aging Neurosci..

[69]  M. Turner,et al.  Inflammation and neurovascular changes in amyotrophic lateral sclerosis , 2013, Molecular and Cellular Neuroscience.

[70]  A. Singleton,et al.  TREM2 variants in Alzheimer's disease. , 2013, The New England journal of medicine.

[71]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[72]  R. Tsien,et al.  Ratiometric Activatable Cell-Penetrating Peptides Provide Rapid In Vivo Readout of Thrombin Activation** , 2012, Angewandte Chemie.

[73]  R. Doolittle,et al.  Correlating structure and function during the evolution of fibrinogen‐related domains , 2012, Protein science : a publication of the Protein Society.

[74]  T. Deerinck,et al.  Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation , 2012, Nature Communications.

[75]  Jesse D. Sengillo,et al.  Blood–spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis , 2012, Acta Neuropathologica.

[76]  A. Pisani,et al.  Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson’s disease , 2012, Journal of Neuroinflammation.

[77]  R. Tsien,et al.  In vivo fluorescence imaging of atherosclerotic plaques with activatable cell-penetrating peptides targeting thrombin activity. , 2012, Integrative biology : quantitative biosciences from nano to macro.

[78]  R. Tsien,et al.  Thrombin Activity Associated with Neuronal Damage during Acute Focal Ischemia , 2012, The Journal of Neuroscience.

[79]  Berislav V. Zlokovic,et al.  Apolipoprotein E controls cerebrovascular integrity via cyclophilin A , 2012, Nature.

[80]  S. Strickland,et al.  Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. , 2012, Blood.

[81]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[82]  I. Mikhailenko,et al.  Identification of VLDLR as a novel endothelial cell receptor for fibrin that modulates fibrin-dependent transendothelial migration of leukocytes. , 2012, Blood.

[83]  P. Scheltens,et al.  Dementia in 2011: Microbleeds in dementia—singing a different ARIA , 2012, Nature Reviews Neurology.

[84]  Christophe Lemetre,et al.  Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. , 2012, Journal of Alzheimer's disease : JAD.

[85]  Yi Zhang,et al.  Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease , 2011, PloS one.

[86]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[87]  J. Szmydynger-Chodobska,et al.  Blood–Brain Barrier Pathophysiology in Traumatic Brain Injury , 2011, Translational Stroke Research.

[88]  K. M. Baeten,et al.  Extracellular matrix and matrix receptors in blood–brain barrier formation and stroke , 2011, Developmental neurobiology.

[89]  S. Liebner,et al.  Current concepts of blood-brain barrier development. , 2011, The International journal of developmental biology.

[90]  Daniel S Reich,et al.  Evolution of the blood–brain barrier in newly forming multiple sclerosis lesions , 2011, Annals of neurology.

[91]  D. Rowitch,et al.  Myelin regeneration: a recapitulation of development? , 2011, Annual review of neuroscience.

[92]  R. Tucker,et al.  Tenascins and the importance of adhesion modulation. , 2011, Cold Spring Harbor perspectives in biology.

[93]  Chengjie Xiong,et al.  Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis , 2011, PloS one.

[94]  S. Lord,et al.  Molecular Mechanisms Affecting Fibrin Structure and Stability , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[95]  D. Davalos,et al.  Fibrinogen as a key regulator of inflammation in disease , 2011, Seminars in Immunopathology.

[96]  Yang Yang,et al.  Fibrinogen Depleting Agent Batroxobin has a Beneficial Effect on Experimental Autoimmune Encephalomyelitis , 2011, Cellular and Molecular Neurobiology.

[97]  Bengt R. Johansson,et al.  Pericytes regulate the blood–brain barrier , 2010, Nature.

[98]  S. Strickland,et al.  Alzheimer's disease peptide β-amyloid interacts with fibrinogen and induces its oligomerization , 2010, Proceedings of the National Academy of Sciences.

[99]  Si-Ming Zhang,et al.  The Primary Role of Fibrinogen-Related Proteins in Invertebrates Is Defense, Not Coagulation , 2010, Journal of Innate Immunity.

[100]  Berislav V. Zlokovic,et al.  Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging , 2010, Neuron.

[101]  M. Verbeek,et al.  Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain Aβ levels , 2010, Neurobiology of Disease.

[102]  Nan Li,et al.  Integrin CD11b negatively regulates TLR-triggered inflammatory responses by activating Syk and promoting degradation of MyD88 and TRIF via Cbl-b , 2010, Nature Immunology.

[103]  Alon Friedman,et al.  Blood–brain barrier breakdown as a therapeutic target in traumatic brain injury , 2010, Nature Reviews Neurology.

[104]  S. Strickland,et al.  Fibrinogen and β-Amyloid Association Alters Thrombosis and Fibrinolysis: A Possible Contributing Factor to Alzheimer's Disease , 2010, Neuron.

[105]  P. Tam,et al.  Extrinsic regulation of pluripotent stem cells , 2010, Nature.

[106]  C. Schachtrup,et al.  Fibrinogen Triggers Astrocyte Scar Formation by Promoting the Availability of Active TGF-β after Vascular Damage , 2010, The Journal of Neuroscience.

[107]  Carson K. Lam,et al.  Embolus extravasation is an alternative mechanism for cerebral microvascular recanalization , 2010, Nature.

[108]  P. Knaus,et al.  BMPs: From Bone to Body Morphogenetic Proteins , 2010, Science Signaling.

[109]  J. Ryu,et al.  A leaky blood–brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain , 2008, Journal of cellular and molecular medicine.

[110]  E. Haacke,et al.  Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. , 2009, Journal of Alzheimer's disease : JAD.

[111]  Robin J. M. Franklin,et al.  Remyelination in the CNS: from biology to therapy , 2008, Nature Reviews Neuroscience.

[112]  J. Ryu,et al.  Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain , 2008 .

[113]  G. Comi,et al.  The extracellular matrix affects axonal regeneration in peripheral neuropathies , 2008, Neurology.

[114]  Peter Caravan,et al.  EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. , 2008, Journal of the American Chemical Society.

[115]  D. Bennett,et al.  LONG-TERM FETAL CELL TRANSPLANT IN HUNTINGTON DISEASE: STAYIN’ ALIVE , 2007, Neurology.

[116]  Sergio E. Baranzini,et al.  Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets , 2008, Nature.

[117]  B. Zlokovic.  The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders , 2008, Neuron.

[118]  G. Xu,et al.  Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment , 2007, International journal of clinical practice.

[119]  I. Shelef,et al.  Blood–brain barrier disruption in post-traumatic epilepsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[120]  H. Lassmann,et al.  Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? , 2007, Brain : a journal of neurology.

[121]  I. Tsigelny,et al.  Fibrinogen signal transduction as a mediator and therapeutic target in inflammation: lessons from multiple sclerosis. , 2007, Current medicinal chemistry.

[122]  J. Melchor,et al.  Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. , 2007 .

[123]  Benjamin D. Sachs,et al.  Fibrinogen inhibits neurite outgrowth via β3 integrin-mediated phosphorylation of the EGF receptor , 2007, Proceedings of the National Academy of Sciences.

[124]  Benjamin D. Sachs,et al.  p75 neurotrophin receptor regulates tissue fibrosis through inhibition of plasminogen activation via a PDE4/cAMP/PKA pathway , 2007, The Journal of cell biology.

[125]  S. Ha,et al.  Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease , 2007, BMC neurology.

[126]  J. Kaye,et al.  Blood–brain barrier impairment in Alzheimer disease , 2007, Neurology.

[127]  H. Lassmann,et al.  The fibrin-derived γ377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease , 2007, The Journal of experimental medicine.

[128]  M. Pepys,et al.  Human plasma fibrinogen is synthesized in the liver. , 2007, Blood.

[129]  S. McQuaid,et al.  Persistent endothelial abnormalities and blood–brain barrier leak in primary and secondary progressive multiple sclerosis , 2007, Neuropathology and applied neurobiology.

[130]  Jonathan Stone,et al.  Microvascular pathology in the aging human brain: Evidence that senile plaques are sites of microhaemorrhages , 2006, Neurobiology of Aging.

[131]  B. Lipiński,et al.  New insight into Alzheimer disease: demonstration of fibrin(ogen)-serum albumin insoluble deposits in brain tissue. , 2006, Alzheimer disease and associated disorders.

[132]  B. Engelhardt,et al.  Dysferlin Is a New Marker for Leaky Brain Blood Vessels in Multiple Sclerosis , 2006, Journal of neuropathology and experimental neurology.

[133]  P. Oschmann,et al.  The impact of interferon-β treatment on the blood-brain barrier , 2006 .

[134]  P. Duquette,et al.  Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: Relevance to multiple sclerosis , 2006, Annals of neurology.

[135]  P. Koolwijk,et al.  Fibrin structure and wound healing , 2006, Journal of thrombosis and haemostasis : JTH.

[136]  S. Strickland,et al.  Exogenous Tissue Plasminogen Activator Enhances Peripheral Nerve Regeneration and Functional Recovery After Injury In Mice , 2006, Journal of neuropathology and experimental neurology.

[137]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.

[138]  F. Barkhof,et al.  Blood–brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis , 2005, Neurobiology of Disease.

[139]  Albert Hofman,et al.  Fibrinogen Is Associated With an Increased Risk of Alzheimer Disease and Vascular Dementia , 2005, Stroke.

[140]  M. Mosesson.  Fibrinogen and fibrin structure and functions , 2005, Journal of thrombosis and haemostasis : JTH.

[141]  Hans Lassmann,et al.  Multiple Sclerosis Pathology: Evolution of Pathogenetic Concepts , 2005, Brain pathology.

[142]  J. Bart,et al.  Blood–brain barrier dysfunction in parkinsonian midbrain in vivo , 2005, Annals of neurology.

[143]  R. Pascual-Marqui,et al.  Focal Cortical Dysfunction and Blood–Brain Barrier Disruption in Patients With Postconcussion Syndrome , 2005, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[144]  Dr. Eduard Rindfleisch,et al.  Histologisches Detail zu der grauen Degeneration von Gehirn und Rückenmark. (Zugleich ein Beitrag zu der Lehre von der Entstehung und Verwandlung der Zelle.) , 1863, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.

[145]  J. Degen,et al.  Fibrin(ogen)-αMβ2 Interactions Regulate Leukocyte Function and Innate Immunity In Vivo , 2004 .

[146]  M. Alessio,et al.  Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. , 2004, Journal of neurotrauma.

[147]  J. Golden,et al.  Oligodendrocyte maturation is inhibited by bone morphogenetic protein , 2004, Molecular and Cellular Neuroscience.

[148]  N. Reiner,et al.  Dual Receptors and Distinct Pathways Mediate Interleukin-1 Receptor-associated Kinase Degradation in Response to Lipopolysaccharide , 2004, Journal of Biological Chemistry.

[149]  Benjamin D. Sachs,et al.  Fibrin mechanisms and functions in nervous system pathology. , 2004, Molecular interventions.

[150]  D. Witte,et al.  Leukocyte engagement of fibrin(ogen) via the integrin receptor αMβ2/Mac-1 is critical for host inflammatory response in vivo , 2004 .

[151]  C. Vergani,et al.  Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease , 2004, The Journal of Neuroscience.

[152]  H. Lassmann,et al.  Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[153]  M. Barnett,et al.  Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion , 2004, Annals of neurology.

[154]  C. Brosnan,et al.  Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis , 2004, Acta Neuropathologica.

[155]  D. Carey,et al.  αVβ8 integrin is a Schwann cell receptor for fibrin , 2003 .

[156]  D. Dickstein,et al.  Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model , 2003 .

[157]  S. McQuaid,et al.  Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood–brain barrier leakage and active demyelination , 2003, The Journal of pathology.

[158]  S. Lord,et al.  Sequence γ377−395(P2), but Not γ190−202(P1), Is the Binding Site for the αMI-Domain of Integrin αMβ2 in the γC-Domain of Fibrinogen† , 2003 .

[159]  M. Cuzner,et al.  Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. , 2003, Brain : a journal of neurology.

[160]  K. Akassoglou,et al.  Fibrin is a regulator of Schwann cell migration after sciatic nerve injury in mice , 2003, Neuroscience Letters.

[161]  W. Gomes,et al.  Transgenic overexpression of BMP4 increases astroglial and decreases oligodendroglial lineage commitment. , 2003, Developmental biology.

[162]  F. Jolesz,et al.  MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals , 2003, Neurology.

[163]  S. Tsirka,et al.  Involvement of Tissue Plasminogen Activator in Onset and Effector Phases of Experimental Allergic Encephalomyelitis , 2002, The Journal of Neuroscience.

[164]  T. Ugarova,et al.  Regulated Unmasking of the Cryptic Binding Site for Integrin αMβ2 in the γC-Domain of Fibrinogen† , 2002 .

[165]  B. Furie,et al.  Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse , 2002, Nature Medicine.

[166]  M. Graves,et al.  Cyclooxygenase‐2‐positive macrophages infiltrate the Alzheimer’s disease brain and damage the blood–brain barrier , 2002, European journal of clinical investigation.

[167]  Pamela L. Follett,et al.  The Toll-Like Receptor TLR4 Is Necessary for Lipopolysaccharide-Induced Oligodendrocyte Injury in the CNS , 2002, The Journal of Neuroscience.

[168]  L. Medved,et al.  Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH2-terminal portions of the fibrin beta chains. , 2002, Biochemistry.

[169]  K. Akassoglou,et al.  Fibrin Inhibits Peripheral Nerve Remyelination by Regulating Schwann Cell Differentiation , 2002, Neuron.

[170]  K. Akassoglou,et al.  Nervous System Pathology: The Fibrin Perspective , 2002, Biological chemistry.

[171]  F. Castellino,et al.  Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. , 2001, The American journal of pathology.

[172]  J. Newcombe,et al.  Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. , 2001, Brain : a journal of neurology.

[173]  W. Hancock,et al.  Fibrinogen Stimulates Macrophage Chemokine Secretion Through Toll-Like Receptor 41 , 2001, The Journal of Immunology.

[174]  G. Tsurupa,et al.  Conformational Changes upon Conversion of Fibrinogen into Fibrin , 2001, Annals of the New York Academy of Sciences.

[175]  C. Lucchinetti,et al.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. , 2001, Trends in molecular medicine.

[176]  Ross L. Cagan,et al.  Scabrous complexes with Notch to mediate boundary formation , 2001, Nature.

[177]  S. Akira,et al.  CD11b/CD18 Acts in Concert with CD14 and Toll-Like Receptor (TLR) 4 to Elicit Full Lipopolysaccharide and Taxol-Inducible Gene Expression1 2 3 , 2001, The Journal of Immunology.

[178]  I. Mochalkin,et al.  A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[179]  J. Mizuguchi,et al.  Fibrinogen Binds to Integrin α5β1via the Carboxyl-Terminal RGD Site of the Aα-Chain , 2000 .

[180]  K. Akassoglou,et al.  Tissue Plasminogen Activator–Mediated Fibrinolysis Protects against Axonal Degeneration and Demyelination after Sciatic Nerve Injury , 2000, The Journal of cell biology.

[181]  White,et al.  Evidence of blood–brain barrier dysfunction in human cerebral malaria , 1999, Neuropathology and applied neurobiology.

[182]  Joseph J. Volpe,et al.  Maturation-Dependent Vulnerability of Oligodendrocytes to Oxidative Stress-Induced Death Caused by Glutathione Depletion , 1998, The Journal of Neuroscience.

[183]  C. Rüegg,et al.  Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes. , 1998, Journal of immunology.

[184]  L. Parnetti,et al.  Activation of the Contact System in Cerebrospinal Fluid of Patients with Alzheimer Disease , 1998, Alzheimer disease and associated disorders.

[185]  P. Sonderegger,et al.  The Axonally Secreted Serine Proteinase Inhibitor, Neuroserpin, Inhibits Plasminogen Activators and Plasmin but Not Thrombin* , 1998, The Journal of Biological Chemistry.

[186]  C. Lucchinetti,et al.  Multiple sclerosis: lessons from neuropathology. , 1998, Seminars in neurology.

[187]  Hans Lassmann,et al.  Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathology , 1997, Annals of neurology.

[188]  N. Yanagisawa,et al.  Fibrin deposition in the central nervous system correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease , 1997, Journal of Neuroimmunology.

[189]  M. Esiri,et al.  The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. , 1997, Brain : a journal of neurology.

[190]  N. Yanagisawa,et al.  Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats , 1996, Journal of Neuroimmunology.

[191]  T. Bugge,et al.  Loss of Fibrinogen Rescues Mice from the Pleiotropic Effects of Plasminogen Deficiency , 1996, Cell.

[192]  M. J. Danton,et al.  Impaired platelet aggregation and sustained bleeding in mice lacking the fibrinogen motif bound by integrin alpha IIb beta 3. , 1996, The EMBO journal.

[193]  R. Ádány,et al.  Fibrin deposition in primary and metastatic human brain tumours. , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[194]  S. Lord,et al.  Dissecting Clot Retraction and Platelet Aggregation , 1996, The Journal of Biological Chemistry.

[195]  L. Lund,et al.  Impaired wound healing in mice with a disrupted plasminogen gene , 1996, Nature Medicine.

[196]  T. Fujita,et al.  A Novel Human Serum Lectin with Collagen- and Fibrinogen-like Domains That Functions as an Opsonin (*) , 1996, The Journal of Biological Chemistry.

[197]  Theodore T. Suh,et al.  Impaired platelet aggregation andsustained bleeding inmicelacking thefibrinogen motifbound byintegrin alIb13 , 1996 .

[198]  L. Languino,et al.  Structural Recognition of a Novel Fibrinogen Chain Sequence (117133) by Intercellular Adhesion Molecule-1 Mediates Leukocyte-Endothelium Interaction (*) , 1995, The Journal of Biological Chemistry.

[199]  J. Prineas,et al.  Blood‐Brain Barrier Abnormalities in Longstanding Multiple Sclerosis Lesions. An Immunohistochemical Study , 1994, Journal of neuropathology and experimental neurology.

[200]  A. Wakefield,et al.  Immunohistochemical study of vascular injury in acute multiple sclerosis. , 1994, Journal of clinical pathology.

[201]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[202]  W. S. Thomas,et al.  Tissue Factor Contributes to Microvascular Defects After Focal Cerebral Ischemia , 1993, Stroke.

[203]  J. Volpe,et al.  Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[204]  R F Doolittle,et al.  A detailed consideration of a principal domain of vertebrate fibrinogen and its relatives , 1992, Protein science : a publication of the Protein Society.

[205]  M. Esiri,et al.  Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. , 1991, Brain : a journal of neurology.

[206]  B E Kendall,et al.  Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. , 1990, Brain : a journal of neurology.

[207]  D. Cheresh,et al.  Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites. , 1990, The Journal of biological chemistry.

[208]  H I Goldberg,et al.  Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. , 1988, Radiology.

[209]  B E Kendall,et al.  Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.

[210]  R. Doolittle.  Fibrinogen and fibrin. , 1981, Scientific American.

[211]  E. Engvall,et al.  Affinity of fibronectin to collagens of different genetic types and to fibrinogen , 1978, The Journal of experimental medicine.

[212]  Paterson Py.  Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. , 1976, Federation proceedings.

[213]  P. Y. Paterson.  Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. , 1976, Federation proceedings.

[214]  Fanny Marhuenda,et al.  CONTACTS , 1967 .

[215]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.

[216]  R. Adams,et al.  The morbid anatomy of the demyelinative diseases , 1952 .

[217]  R. D. Adams,et al.  The morbid anatomy of the demyelinative disease. , 1952, American Journal of Medicine.